X
30.64
-2.91 (-8.67%)
Penutupan Terdahulu | 33.55 |
Buka | 33.57 |
Jumlah Dagangan | 1,095,883 |
Purata Dagangan (3B) | 449,290 |
Modal Pasaran | 2,345,271,296 |
Harga / Buku (P/B) | 3.61 |
Julat 52 Minggu | |
Tarikh Pendapatan | 7 May 2025 - 12 May 2025 |
EPS Cair (TTM) | -3.01 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 1.19% |
Nisbah Semasa (MRQ) | 17.85 |
Aliran Tunai Operasi (OCF TTM) | -181.39 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -117.59 M |
Pulangan Atas Aset (ROA TTM) | -19.80% |
Pulangan Atas Ekuiti (ROE TTM) | -27.85% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Bercampur | |
Stok | Xenon Pharmaceuticals Inc. | Menaik | Menaik |
AISkor Stockmoo
1.9
Konsensus Penganalisis | 5.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 5.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | -2.5 |
Purata | 1.88 |
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Mid Core |
% Dimiliki oleh Orang Dalam | 0.37% |
% Dimiliki oleh Institusi | 103.63% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 67.00 (Deutsche Bank, 118.67%) | Beli |
Median | 60.00 (95.82%) | |
Rendah | 53.00 (HC Wainwright & Co., 72.98%) | Beli |
Purata | 60.00 (95.82%) | |
Jumlah | 2 Beli | |
Harga Purata @ Panggilan | 38.38 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 24 Feb 2025 | 53.00 (72.98%) | Beli | 38.37 |
Deutsche Bank | 11 Feb 2025 | 67.00 (118.67%) | Beli | 38.39 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
04 Apr 2025 | Pengumuman | Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 |
12 Mar 2025 | Pengumuman | Xenon to Present at Stifel 2025 Virtual CNS Forum |
27 Feb 2025 | Pengumuman | Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update |
25 Feb 2025 | Pengumuman | Xenon to Present at the 45th Annual TD Cowen Healthcare Conference |
20 Feb 2025 | Pengumuman | Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025 |
13 Jan 2025 | Pengumuman | Xenon Outlines Key Corporate Milestone Opportunities for 2025 |
07 Jan 2025 | Pengumuman | Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |